Physician profile
Trisha E Durham
NPI 1891113247
$5,413.43
in general payments reported to CMS, 2019-2025
12 companies · $396 in 2025
The $396 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $287 · 2022: $2,436 · 2023: $530 · 2024: $1,764 · 2025: $396.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,568 · Travel and Lodging: $1,122.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,568.40 |
| Travel and Lodging | $1,122.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nalu Medical, INC. | $1,839.16 | 2021-2024 | Nalu Neurostimulation System |
| Boston Scientific Corporation | $1,586.70 | 2021-2023 | Wavewriter Alpha Prime 16, Superion Indirect Decompression System |
| Spinal Simplicity, LLC | $1,110.19 | 2022-2025 | Ha Minuteman G3-R |
| Abbvie INC. | $208.44 | 2024-2025 | |
| Grt US Holding, INC. | $182.37 | 2021-2022 | |
| Kerecis Limited | $139.53 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Medtronic, INC. | $114.57 | 2022-2025 | Inceptiv |
| Stimwave Technologies Incorporated | $88.43 | 2021-2022 | |
| Averitas Pharma INC. | $65.59 | 2024 | Qutenza |
| Nevro Corp. | $39.51 | 2021 | |
| Organogenesis INC. | $21.84 | 2025 | Apligraf |
| Collegium Pharmaceutical, INC. | $17.10 | 2025 | Belbuca |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Trisha Durham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.